BOTHELL, Wash., Dec. 12 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX - News), a global leader in advanced cardiac monitoring and defibrillation products, today announced that it has successfully completed the planned integration of both customer service and manufacturing activities as part of its recent merger.
Cardiac Science has now fully transitioned all automated external defibrillator (AED) manufacturing to its Deerfield, WI facility, validated the new line, and achieved full production as of last week. The company has also successfully configured product orders for both domestic and international markets on the new line.
In addition, the company has completed the transition of all service and administrative functions to its headquarters in Bothell, WA. Since November 1, all customer orders have been processed in Bothell. All technical support services are currently managed from either Bothell or Deerfield.
“The successful completion of our consolidation on schedule represents a significant milestone in our overall plan to combine the predecessor companies and will yield significant cost savings,” said John Hinson, chief executive officer of Cardiac Science Corporation. “We now intend to turn our full attention to growing our business.”
The merger of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. was completed on September 1, 2005.
About Cardiac Science Corporation
Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -- defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services.
The company is the successor to various entities that have owned and operated cardiology related businesses, which sold products under the trusted brand names Burdick®, Powerheart®, and Quinton®. Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, those relating to cost savings that are expected to be realized and future growth of the business of Cardiac Science Corporation, that involve a number of risks and uncertainties. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “intend,” anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption “Risk Factors,” and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions “Certain Factors that May Affect Future Results” and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Media Contacts Mike Matysik Cardiac Science Corp. Sr.Vice President and CFO 425-402-2009
Lora Lee The Fearey Group for Cardiac Science Corp. 206-343-1543
Source: Cardiac Science Corporation
